精蛋白锌重组赖脯胰岛素联合α-糖苷酶抑制剂治疗对肥胖性2型糖尿病患者FPG及2hPG水平的影响  

Effect of protamine zinc recombinant lysine insulin combined with a-glucosidase inhibitor on FPG and 2 hPG levels in obese type 2 diabetic patients

作　　者：高伟 陶磊[1] 刘怡 尚军洁[1] Gao Wei;Tao Lei;Liu Yi;Shang Junjie(Nanyang Second People's Hospital,Nanyang 473000,Henan,China)

机构地区：[1]南阳市第二人民医院,河南南阳473000

出　　处：《临床心身疾病杂志》2019年第6期4-6,共3页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨精蛋白锌重组赖脯胰岛素联合α-糖苷酶抑制剂治疗对血糖控制不佳肥胖性2型糖尿病患者空腹血糖、餐后2h血糖水平的影响.方法将116例肥胖性2型糖尿病患者按随机数字表法分为两组,每组58例.两组均予以精蛋白锌重组赖脯胰岛素治疗,观察组在此基础上联合α-糖苷酶抑制剂阿卡波糖治疗.比较治疗前后两组空腹血糖、餐后2h血糖、糖化血红蛋白及血清趋化素、内脂素水平,并统计两组不良反应发生状况.结果治疗后观察组餐后2h血糖、糖化血红蛋白及血清趋化素、内脂素水平显著低于对照组(P<0.05或0.01).观察组不良反应发生率为10.3%,对照组为5.2%,两组比较差异无统计学意义(P>0.05).结论精蛋白锌重组赖脯胰岛素联合α-糖苷酶抑制剂可下调肥胖性2型糖尿病患者趋化素、内脂素表达,降低患者餐后2h血糖、糖化血红蛋白水平,疗效显著,安全性高.Objective To observe the effects of protamine zinc recombinant lysine insulin combined with aglucosidase inhibitor on fasting blood glucose(FPG)and postprandial 2 h blood glucose(2 hPG)levels in obese type 2 diabetic patients.Methods A total of 116 patients with obesity T2DM were divided into two groups according to the random number table,with 58 cases in each group.The control group was treated with protamine zinc recombinant lysine insulin,and the observation group was treated with the α-glucosidase inhibitor acarbose on the basis of the control group.The incidence of adverse reactions,FPG,2 h PG,HbA1c levels,serum chcmokinc,and visfatin levels were compared before and after treatment.Results After treatment,2 h PG,glycosylated hemoglobin,serum chemokine and visfatin levels in the observation group were significantly lower than those in the control group(P<0.05 or 0.01).The incidence of adverse reactions was 10.3% in the observation group and 5.2% in the control group.There was no significant difference between the two groups(P>0.05).Conclusions Protamine zinc recombinant lysine combined with α-glucosidase inhibitor in patients with poor glycemic control of obese T2DM can down-regulate the expression of chemerin and visfatin,and reduce the levels of 2 h PG and HbAlc in patients with high safety.

关 键 词：2型糖尿病 血糖控制不佳 肥胖 精蛋白锌重组赖脯胰岛素 α-糖苷酶抑制 

分 类 号：R587.1[医药卫生—内分泌]